## CONTENTS

### Special Lecture

1079 **There Are No Bad Anticancer Agents, Only Bad Clinical Trial Designs—Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.** Daniel D. Von Hoff.

### Review Article


### Advances in Brief

1101 **Combined Analysis of Studies of the Effects of the Matrix Metalloproteinase Inhibitor Marimastat on Serum Tumor Markers in Advanced Cancer: Selection of a Biologically Active and Tolerable Dose for Longer-term Studies.** John Nemunaitis, Christopher Poole, John Primrose, Alexander Rosemurgy, John Mafelatano, Peter Brown, Amy Berrington, Alan Comish, Kevin Lynch, Henrik Rasmussen, David Kerr, David Cox, and Andrew Millar.

1111 **High Raf-1 Kinase Activity Protects Human Tumor Cells against Paclitaxel-induced Cytotoxicity.** Aghdass Rasouli-Nia, Dan Liu, Sherry Perdue, and Richard A. Britten.

### Research Articles

1117 **Antibody Responses in Melanoma Patients Immunized with an Anti-Idiotype Antibody Mimicking Disialoganglioside GD2.** Kenneth A. Foon, Goutam Sen, Laura Hutchins, Oscar L. Kashala, Rathin Baral, Mairayee Banerjee, Mala Chakraborty, Juanita Garrison, Ralph A. Reisfeld, and Malaya Bhattacharya-Chatterjee.


1147 **Infrequent Expression of p21 Is Related to Altered p53 Protein in Pancreatic Carcinoma.** Yu-Xin Hu, Hiroki Watanabe, Koushiro Ohtsuhito, Yasushi Yamaguchi, Aiguli Ha, Yoshiharu Motoo, Takashi Okai, and Norio Sawabu.


1183 **Phase I Trial of Subcutaneous Recombinant Human Interleukin-12 in Patients with Advanced Renal Cell Carcinoma.** Robert J. Motzer, Ashok Rakhit, Lawrence H. Schwartz, Thomas Olencki, Thomas M. Malone, Kate Sandstrom, Rosemary Nadeau, Harshuk Parmar, and Ronald Bukowski.

1193 **Phase I Study of Suramin Combined with Doxorubicin in the Treatment of Androgen-independent Prostate Cancer.** Shi-Ming Tu, Lance C. Paghiaro, Marie E. Banks, Robert J. Amato, Randall E. Millikan, Nagla A. Bugazia, Timothy Madden, Robert A. Newman, and Christopher J. Logothetis.

1203 **A Two-Part Phase I Trial of High-Dose Interleukin 2 in Combination with Soluble (Chinese Hamster Ovary) Interleukin 1 Receptor.** David F. McDermott, Elizabeth G. Trebu, James W. Mier, Damian Sorce, William Rand, Lucie Ronayne, Kerry Kappler, Marguerite Clancy, Mark Klempner, and Michael B. Atkins.


1221 **Evaluation of the Balance between Angiogenic and Antiangiogenic Circulating Factors in Patients with Breast and Gastrointestinal Cancers.** Daniele Morelli, Debora Lazzerini, Sara Cazzaniga, Paolo Squisciarini, Paola Bignami, Jeanette A. M. Maier, Lucia Sfondrini, Sylvie Ménard, Maria I. Colnaghi, and Andrea Balsari.

Patients with Isolated Trisomy 8 in Acute Myeloid Leukemia Are Not Cured with Cytarabine-based Chemotherapy: Results from Cancer and Leukemia Group B 8461. John C. Byrd, David Lawrence, Diane C. Arthur, Mark J. Pettenati, Ramana Tantravahi, Mazin Qumsiyeh, Judith Stamberg, Frederick R. Davey, Charles A. Schiffer, and Clara D. Bloomfield.


Loss of p21WAF1/Cip1 Protein Expression Accompanies Progression of Sporadic Colorectal Neoplasms but not Hereditary Nonpolyposis Colorectal Cancers. Frank A. Sinicrope, Gardiner Roddey, Michael Lemoine, Sanbao Ruan, L. Clifton Stephens, Marsha L. Frazier, Yu Shen, and Wei Zhang.


Antiangiogenic Chemotherapeutic Agents: Characterization in Comparison to Their Tumor Growth Inhibition in Human Renal Cell Carcinoma Models. Michael Schirmer, Jens Hoffmann, Andreas Menrad, and Martin R. Schneider.

Successful Treatment of Human Chronic Lymphocytic Leukemia Xenografts with Combination Biological Agents Auristatin PE and Bryostatin 1. Ramzi M. Mohammad, Mary L. Varterasian, Victor P. Almatchy, Ghadeer N. Hannoudi, George R. Pettit, and Ayad Al-Katib.


AACR Bulletin Board
Institution of Page Charges
1999 Annual Meeting
Call for Nominations for 1999 AACR-Pezcoller International Award for Cancer Research
Call for Nominations for AACR Awards
AACR Special Conferences in Cancer Research

Author Index

Instructions for Authors